Recombinant Human ANXA4 293 Cell Lysate
- Gene Information
- Related Products
|Description :||Antigen standard for annexin A4 (ANXA4) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.|
|Source :||HEK 293 cells|
|Components :||This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).|
|Size :||0.1 mg|
|Storage Instruction :||Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.|
|Applications :||ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.|
|Gene Name :||ANXA4 annexin A4 [ Homo sapiens ]|
|Official Symbol :||ANXA4|
|Synonyms :||ANXA4; annexin A4; ANX4; P32.5; PP4-X; PAP-II; annexin-4; protein II; endonexin I; lipocortin IV; chromobindin-4; 35-beta calcimedin; proliferation-inducing gene 28; proliferation-inducing protein 28; placental anticoagulant protein II; carbohydrate-binding protein p33/p41; annexin IV (placental anticoagulant protein II); PIG28; ZAP36; MGC75105; DKFZp686H02120;|
|Gene ID :||307|
|mRNA Refseq :||NM_001153|
|Protein Refseq :||NP_001144|
|UniProt ID :||P09525|
|Chromosome Location :||2p13.3|
|Pathway :||Prostaglandin Synthesis and Regulation, organism-specific biosystem;|
|Function :||calcium ion binding; calcium ion binding; calcium-dependent phospholipid binding; calcium-dependent phospholipid binding; calcium-dependent phospholipid binding; phospholipase inhibitor activity;|
|◆ Recombinant Protein|
|ANXA4-346H||Recombinant Human ANXA4 Protein, His (Fc)-Avi-tagged||+Inquiry|
|ANXA4-584M||Recombinant Mouse ANXA4 Protein, His (Fc)-Avi-tagged||+Inquiry|
|ANXA4-167H||Recombinant Human ANXA4 Protein, His-tagged||+Inquiry|
|Anxa4-608M||Recombinant Mouse Anxa4 Protein, MYC/DDK-tagged||+Inquiry|
|ANXA4-167R||Recombinant Rhesus Macaque ANXA4 Protein, His (Fc)-Avi-tagged||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (17)Ask a question
Yes, ANXA4 has been shown to interact with several proteins and lipids. It can bind to phospholipids such as phosphatidylserine and phosphatidylinositol, which are important for its membrane association. ANXA4 can also interact with other annexin proteins or cytoskeletal proteins, potentially contributing to its diverse cellular functions.
The expression of ANXA4 can be regulated by various factors, including cellular differentiation, hormones, and cytokines. Additionally, it can be influenced by environmental factors, such as changes in calcium levels and cellular stress.
Yes, ANXA4 can undergo post-translational modifications such as phosphorylation and acetylation. These modifications can affect the protein's stability, subcellular localization, and interactions with other molecules, potentially modulating its cellular functions.
ANXA4 has been implicated in several diseases and conditions. It has been linked to the pathogenesis of atherosclerosis, where it plays a role in lipid metabolism and plaque formation. ANXA4 has also been associated with certain cancers, such as gastric cancer and breast cancer, where it may influence tumor growth and metastasis.
Genetic variants and mutations in the ANXA4 gene have been identified in some studies. These genetic alterations may contribute to individual differences in ANXA4 expression or function, potentially impacting disease susceptibility or progression. Further research is needed to fully understand the significance of these genetic variations.
Yes, ANXA4 appears to play a role in cell adhesion and migration. It has been associated with the regulation of focal adhesions and actin cytoskeleton dynamics, processes crucial for cell movement and tissue remodeling. ANXA4 may modulate these processes through its interaction with cytoskeletal components and signaling pathways.
ANXA4 has shown potential as a diagnostic or prognostic marker in certain diseases. For example, its expression levels have been correlated with clinical outcomes in breast cancer and ovarian cancer. However, more research is needed to validate its utility and establish standardized protocols for its use as a diagnostic or prognostic marker in different contexts.
Genetic variants and mutations in ANXA4 have been reported in certain individuals. These variants can occur in the coding sequence of the gene and may lead to alterations in the protein structure or function. Studies investigating the functional impact of these genetic variants and their association with specific diseases are still ongoing.
ANXA4 has the ability to bind calcium ions, and this binding triggers conformational changes in the protein that allow it to interact with other molecules or membranes. These calcium-dependent interactions are essential for the regulation of various cellular processes, including vesicle fusion, exocytosis, and intracellular signaling.
Yes, the ANXA4 protein is evolutionarily conserved and found in many species, including mammals, birds, reptiles, and fish. The high degree of conservation suggests its important biological functions across different organisms.
Yes, ANXA4 is involved in several physiological processes. It has been implicated in the regulation of oocyte maturation, sperm function, and embryonic development. ANXA4 also plays a role in the physiology of the female reproductive tract, including endometrial receptivity and embryo implantation.
Yes, ANXA4 can be detected in various biological samples, including blood, tissues, and cell culture supernatants. Detection methods like immunohistochemistry, Western blotting, and enzyme-linked immunosorbent assays (ELISA) can be used to quantify ANXA4 levels. However, the specific method of detection may vary depending on the research or diagnostic context.
The expression of ANXA4 can be regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational mechanisms. Transcriptional regulation can be influenced by various factors and signaling pathways, such as hormones, growth factors, and inflammatory mediators. Post-transcriptional regulation can occur through mechanisms like mRNA stability, alternative splicing, and microRNA-mediated regulation. Post-translational modifications, as mentioned earlier, can also impact ANXA4 expression by affecting its stability and activity.
Dysregulation of ANXA4 has been implicated in various diseases and conditions. For example, altered ANXA4 expression has been observed in cancers, including breast cancer, ovarian cancer, and lung cancer, where it can contribute to tumor progression and metastasis. ANXA4 dysregulation has also been associated with cardiovascular diseases, inflammation, and autoimmune conditions, highlighting its involvement in diverse pathophysiological processes.
Ongoing studies and research areas related to ANXA4 include investigating its role in cancer biology, understanding its functions in reproductive physiology and fertility, exploring its involvement in cardiovascular diseases and inflammation, and exploring its potential as a therapeutic target. Researchers are also investigating the mechanisms of ANXA4 regulation and its interactions with other molecules.
ANXA4 has shown potential as a biomarker in certain diseases, including gastric cancer and atherosclerosis. It may serve as an indicator of disease progression or prognosis. As for therapeutic targeting, the specific role of ANXA4 in disease pathogenesis is still being investigated, and it has not yet emerged as a primary target for therapy.
The dysregulation of ANXA4 in certain diseases suggests that it could be a potential therapeutic target. Modulating ANXA4 expression or activity may offer opportunities for developing novel treatments. Additionally, ANXA4 itself could serve as a therapeutic agent or biomarker for specific conditions. However, further research is needed to better understand the precise mechanisms of ANXA4 and its therapeutic potential.
Customer Reviews (4)Write a review
They are readily available to address any concerns or questions and supply valuable resources to assist in experimental design and optimization. -
Their expertise in protein production and purification ensures the delivery of a high-quality product that consistently performs well in my experiments. -
Should I encounter any challenges or require technical assistance, the manufacturer provides prompt and knowledgeable support. -
the manufacturer offers a wide range of ANXA4 protein variants, including recombinant or native forms, as well as different conjugates and modifications. -
Ask a Question for All ANXA4 Products
Required fields are marked with *
My Review for All ANXA4 Products
Required fields are marked with *